# A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

> **NCT02754362** · PHASE2 · WITHDRAWN · sponsor: **NYU Langone Health**

## Conditions studied

- Glioblastoma
- Glioma

## Interventions

- **DRUG:** Bevacizumab
- **BIOLOGICAL:** Peptide Vaccine
- **DRUG:** Poly-ICLC as immune adjuvant
- **DRUG:** Keyhole limpet hemocyanin (KLH)

## Key facts

- **NCT ID:** NCT02754362
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to personnel changes / departure of Dr. Chi.
- **Last updated:** 2020-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02754362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02754362, "A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02754362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*